#For patients
Written for adults considering a peptide as part of their health management.
Tirzepatide: PERCEPTIONS survey findings
The PERCEPTIONS survey (n=518, US) found health improvement was the top reason patients started tirzepatide; cost and insurance were the main barriers.
Mounjaro on X: who shapes the conversation
A 2026 study of 5,566 Mounjaro tweets found that the top influencers on X are patients and public figures, not clinicians.
TB-500 cost in the Netherlands
TB-500 has no EU marketing authorisation and no Dutch insurance coverage. No verified pharmacy price exists in the Netherlands.
What Semax costs in the Netherlands
Semax has no EMA or CBG-MEB authorisation, so there is no official Dutch pharmacy price and no GVS reimbursement. Here is what that means for Dutch readers.
Why Dr. Reddy's paused generic semaglutide
Dr. Reddy's paused generic semaglutide after flagging an API quality issue. Here is what that means for patients, prescribers, and the generic GLP-1 market.
GLP-1 drugs, menstrual changes: FAERS 2026
A July 2026 FAERS study found semaglutide carries broader menstrual signals than tirzepatide or liraglutide, but the data cannot establish causation.
GLP-1 Drugs and Menstrual Changes
A 2026 FAERS study found semaglutide and tirzepatide linked to menstrual adverse events in females aged 12-55, adding a new dimension to GLP-1 counseling.
Real-world semaglutide: dose and dropout
A Danish study of 206 patients found 38% permanently stopped semaglutide within 12 months; 70% of continuers used doses below the 2.4 mg approved maximum.
GLP-1 telehealth prescribing oversight
A Yale JAMA secret-shopper study flagged GLP-1 telehealth sites for thin clinical oversight. Here is what peer-reviewed evidence shows about platform quality.
Syringes for subcutaneous peptide injection
Syringe volume, needle gauge, and length each affect subcutaneous delivery. Here is what GLP-1 prescribing information and CDC injection safety guidance say.
What is tesamorelin?
Tesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy. Plain-English guide to its mechanism, one approved indication, and what the Phase 3 trials found.
What BPC-157 costs in Denmark
BPC-157 has no marketing authorisation in Denmark: no official price, no pharmacy route, no reimbursement. What the grey-market reality looks like.